myTomorrows, global online facilitator of early access to investigational drugs, has introduced an openly accessible API to open up its comprehensive database of uniform information relating to clinical trials. Data on over 300,000 clinical trials, already accessible via its patient and physician centric website, can now be used by other organisations in their own environments. “Opening the myTomorrows database is a big push forward to make comprehensive and uniform information on clinical trials freely accessible to anybody who needs it. We hope to see further applications grow out of our data to better serve unmet medical needs globally and advance drug development” COO Robert Kraal explains, setting out myTomorrows’ hopes for the development. The interface can be used to search, filter, and download complete historic clinical trial records data accumulated from all the registries of the World Health Organization’s Primary Registry Network of medical trial registration partners. Potential applications include anything from ad-hoc queries by data scientists to patient trial screening to mobile health. “We have built the API with the intention of making it accessible for the largest group of stakeholders. Using a very simple approach, any programmer can directly access the data in a friendly human-readable format and structure” says Sander Nagtegaal, Chief Technical Officer at myTomorrows. For technical details, please visit the official documentation, the API terms of service or reach out to tech@mytomorrows.com directly.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.